Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.

Authors:
Flint A; Nazzal K; Jagielski P; Hindsberger C; Zdravkovic M.

Journal:
Br J Clin Pharmacol

Publication Year: 2010

DOI:
10.1111/j.1365-2125.2010.03762.x

PMCID:
PMC2997321

PMID:
21175436

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Br J Clin Pharmacol

Abbreviation: Br J Clin Pharmacol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel reti…
Goncalves MB; Mant T; Täubel J and 8 more (2023) - Transparency Score: 4/6
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastati…
Lehtisalo M; Taskinen S; Tarkiainen EK and 8 more (2022) - Transparency Score: 3/6
A crossover study evaluating the sex-dependent and sensitizing effects of sleep deprivation using a…
Hijma H; Koopmans I; Klaassen E and 3 more (2022) - Transparency Score: 4/6
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in pat…
Baakman AC; Gavan C; van Doeselaar L and 12 more (2022) - Transparency Score: 4/6
An e-Delphi study to obtain expert consensus on the level of risk associated with preventable e-pre…
Heed J; Klein S; Slee A and 3 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests AF, CH and MZ are employed by Novo Nordisk and hold stocks in the company. KN and PJ received financial support for conducting this study from Novo Nordisk A/S, the developer of liraglutide."

Evidence found in paper:

"The authors accept direct responsibility for this paper and are grateful for the contribution made by Watermeadow Medical (supported by Novo Nordisk A/S, Bagsvaerd, Denmark) in developing the draft manuscript from an agreed outline and in collating comments. Competing interests: AF, CH and MZ are employed by Novo Nordisk and hold stocks in the company. KN and PJ received financial support for conducting this study from Novo Nordisk A/S, the developer of liraglutide."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025